Sci. Signal., 23 August 2011
Cancer Making Better Antibodies Through Inhibition
Kristen L. Mueller
Science, AAAS, Washington, DC 20005, USA
Immunotherapies that promote antitumor immunity—including cancer vaccines, adoptive cellular therapies, and monoclonal antibodies—are increasingly being pursued in the clinic to treat a variety of cancers. One monoclonal antibody that is of particular interest is an agonist antibody specific for CD40, a member of the tumor necrosis family of receptors, which has shown modest efficacy in small clinical trials. Antibody ligation of CD40 promotes maturation of antigen-presenting cells, which in turn can drive enhanced T cell– and macrophage-mediated tumor toxicity. Li and Ravetch (see the Perspective by Smyth and Kershaw) now show that optimal antitumor immunity in a variety of mouse models required that the Fc portion of the CD40 antibody engaged the Fc receptor, FcRIIB. This was unexpected because FcRIIB typically transduces inhibitory signals to immune cells. Engineering of antibodies that preferentially bind activating Fc receptors showed that only the inhibitory Fc receptor was able to mediate an antitumor effect. Thus, careful engineering of the Fc region should be considered when designing monoclonal antibody therapeutics.
Citation: K. L. Mueller, Making Better Antibodies Through Inhibition. Sci. Signal. 4, ec232 (2011).
The editors suggest the following Related Resources on Science sites:
In Science Signaling
Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882